Key points are not available for this paper at this time.
Independent of blood pressure, the subclinical PA biochemical phenotype is associated with an increased risk of MACE. Future studies are necessary to determine whether early identification and targeted treatment of subclinical PA mitigates this risk.
Goupil et al. (Wed,) studied this question.